This PubMed entry describes a modeling study titled Cost-effectiveness of pirfenidone for patients with cancer and grade 2 or grade 3 radiation-induced lung injury. The article is published in PLoS Medicine (2026 Aug 5;23(8):e1004817). Bibliographic identifiers provided in the source are PubMed PMID 42555672 and DOI 10.1371/journal.pmed.1004817. The record indicates the article is part of an eCollection for August 2026.
The title and the limited opening of the abstract indicate that the study addresses the cost-effectiveness of the antifibrotic agent pirfenidone for patients with cancer who develop grade 2 or grade 3 radiation-induced lung injury (RILI). The PubMed excerpt begins the abstract with a Background sentence referencing a recent phase II randomized clinical study, implying the modeling study built on clinical trial data or clinical evidence. No further content of the abstract is available in the provided source.
The author list is provided in full in the PubMed record and is led by Qiu-Yi Pan. Coauthors include Ya-Xue Wang, Xue-Ying Tang, Zan Hou, Bai-Qiang Dong, Qi-Wen Li, Bao-Qing Chen, Shou-Min Bai, Chen-Fei Wu, and Ming Chen. Affiliations reported in the source include Sun Yat-sen University Cancer Center, the United Laboratory of Frontier Radiotherapy Technology of Sun Yat-sen University & Chinese Academy of Sciences Ion Medical Technology Co., Ltd., Sun Yat-sen Memorial Hospital Department of Radiation Oncology, and the Department of Radiation Oncology at Sichuan Cancer Hospital & Institute among others. These institutional details are explicitly reported in the PubMed entry.
The PubMed record classifies the work as a modeling study evaluating pirfenidone for grade 2 or grade 3 RILI. Beyond that high-level characterization, the source does not supply the modeling structure, perspective (healthcare payer, societal), time horizon, population size, model inputs (costs, utilities, transition probabilities), or whether deterministic or probabilistic sensitivity analyses were performed. The abstract's first sentence references a recent phase II randomized clinical trial, suggesting clinical outcomes or effectiveness inputs may have been derived from that trial, but the specific trial details and how its data were incorporated into the model are not present in the provided excerpt.
The provided PubMed page is truncated: it contains header information, author and affiliation listings, citation metadata, and the opening line of the abstract only. Critical elements of a full abstract — including methods, primary model outcomes (for example, incremental cost-effectiveness ratios or net monetary benefit), key results, and the authors’ conclusions — are not present in the available text. Therefore, no numerical results, conclusions on cost-effectiveness, or policy recommendations can be extracted from this source alone. Any specific figures, outcome measures, or statistical findings were not reported in the PubMed excerpt supplied.
Because essential data (model assumptions, input values, results, uncertainty analyses) are absent from the source text, clinical interpretation or policy translation is not possible based solely on this PubMed record. The title and metadata establish the study’s topic and publication details but do not provide evidence to support clinical decision making about the use of pirfenidone for RILI. Readers should not assume effectiveness or cost-effectiveness results without consulting the full article.
To obtain complete information on the model design, cost and outcome inputs, sensitivity analyses, and authors’ conclusions, clinicians and policymakers should retrieve the full text of the PLoS Medicine article via the DOI 10.1371/journal.pmed.1004817, institutional subscriptions, or open-access availability. The PubMed entry confirms the article details needed to locate the full publication (journal, date, volume/issue, eCollection number, DOI, and PMID).
Note: The above summary adheres strictly to the information present in the PubMed record provided. Specific study methods, numeric results, and authors’ conclusions were not reported in the available source text and therefore are not included here. For full clinical and economic details, consult the complete PLoS Medicine article.